Corporate Presentation of Ph1b/2a DME Trial Data (ASRS)
Filed with ASX · · 25 pages · English
In the deck
Story so far
Earlier from Opthea
- S&P DJI Announces June 2020 Quarterly Rebalance
- Opthea Reports Positive Ph2a Trial Results of OPT-302 in DME
- Opthea Completes Patient Dosing in Phase 2a DME Trial
- Opthea Completes Recruitment in Ph2a Trial of OPT-302 in DME
- Opthea Equity Raising Presentation
Later from Opthea
- Opthea Completes Successful FDA and EMA Meetings for Phase 3
- Opthea Announces Plans for Potential US listing and IPO
- Opthea Full Year Financial Report 2020
- Opthea Files Registration Statement for Proposed US IPO
- Results of Meeting
Follow Opthea into a list and get an email when it puts out news.
Follow Opthea